Factors related to advanced stage of cancer presentation in Botswana
Date
2018-12Author
Anakwenze, Chidinma
Bhatia, Rohini
Rate, William
Bakwenabatsile, Lame
Ngoni, Kebatshabile
Rayne, Sarah
Dhillon, Preet
Narasimhamurthy, Mohan
Ho-Foster, Ari
Ramogola-Masire, Doreen
Grover, Surbhi
Publisher
American Society of Clinical Oncology, https://beta.asco.org/Rights
Licensed under the Creative Commons Attribution 4.0 LicenseRights holder
AuthorsType
Published ArticleMetadata
Show full item recordAbstract
Purpose: Botswana, a country with a high prevalence of HIV, has an increasing incidence of cancer related mortality in the post–antiretroviral therapy era. Despite universal access to free healthcare, the majority of Botswana patients with cancer present at advanced stages. This study was designed to explore the factors related to advanced-stage cancer presentation in Botswana.
Methods: Patients attending an oncology clinic between December 2015 and January 2017 at Princess Marina Hospital in Gaborone, Botswana, completed a questionnaire on sociodemographic and clinical factors as well as cancer-related fears, attitudes, beliefs, and stigma. Odds ratios (ORs) were calculated to identify factors significantly associated with advanced stage (stage III and IV) at diagnosis.
Results: Of 214 patients, 18.7% were men and 81.3% were women. The median age at diagnosis was 46 years, with 71.9% of patients older than 40 years. The most commonly represented cancers included cervical (42.3%), breast (16%), and head and neck (15.5%). Cancer stages represented in the study group included 8.4% at stage I, 19.2% at stage II, 24.1% at stage III, 11.9% at stage IV, and 36.4% at an unknown stage. Patients who presented at advanced stages were significantly more likely to not be afraid of having cancer (OR, 3.48; P < .05), believe that their family would not care for them if they needed treatment (OR, 6.35; P = .05), and believe that they could not afford to develop cancer (OR, 2.73; P < .05). The perception that symptoms were less
serious was also significantly related to advanced stage (P < .05). Patients with non–female specific cancers were more likely to present in advanced stages (OR, 5.67; P < .05).
Conclusion: Future cancer mortality reduction efforts should emphasize cancer symptom awareness and early detection through routine cancer screening, as well as increasing the acceptability of care-seeking, especially among male patients.
Collections
Related items
Showing items related by title, author, creator and subject.
-
HIV infection and survival among women with cervical cancer
Drysen-Peterson, Scott; Bvochora-Nsingo, Memory; Suneja, Gita; Efstathiou, Jason, A.; Grover, Surbhi; Chiyapo, Sebathu; Ramogola-Masire, Doreen; Kebabonye-Pusoentsi, Malebogo; Clayman, Rebecca; Mapes, Abigail, C.; Tapela, Neo; Asmelash, Aida; Medhin, Heluf; Viswanathan, Akila, N.; Russell, Anthony H.; Lin, Lilie, L.; Kayembe, Mukendi K.A.; Mmalane, Mompati; Randall, Thomas C.; Chabner, Bruce; Lockman, Shahin (American Society of Clinical Oncology, https://beta.asco.org/, 2016-08-29)Purpose Cervical cancer is the leading cause of cancer death among the 20 million women with HIV worldwide. We sought to determine whether HIV infection affected survival in women with invasive cervical cancer. Patients ... -
Impact of human immunodeficiency virus infection on survival and acute toxicities from chemoradiation therapy for cervical cancer patients in a limited-resource setting
Grover, Surbhi; Yeager, Alyssa; Chiyapo, Sebathu; Bhatia, Rohini; MacDuffie, Emily; Puri, Priya; Balang, Dawn; Ratcliffe, Sarah; Narasimhamurthy, Mohan; Gwangwava, Elliphine; Tsietso, Sylvia; Kayembe, Mukendi K.A.; Ramogola-Masire, Doreen; Dryden-Peterson, Scott; Lin, Lilie L.; Zetola, Nicola M.; Viswanathan, Akila N.; Mahantshetty, Umesh (Elsevier, https://www.elsevier.com/en-xm, 2018-05-01)Purpose—To prospectively compare survival between human immunodeficiency virus (HIV)-infected versus HIV-uninfected cervical cancer patients who initiated curative chemoradiation therapy (CRT) in a limited-resource ... -
Assessing nurses’ adherence to the see-and-treat guidelines of Botswana's national cervical cancer prevention programme
Johnson, Lauren G.; Ramogola-Masire, Doreen; Teitelman, Anne M.; Jemmott, John B.; Buttenheim, Alison M. (American Association for Cancer Research, https://www.aacr.org/, 2019-12-18)The see-and-treat approach for cervical cancer screening (VIA followed by immediate cryotherapy) was first pilot tested in Botswana in 2009. Botswana’s Ministry of Health and the Botswana-UPenn Partnership collaborated to ...

